Benjamin Hohl, CFO, on June 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $263,577. Following the Form 4 filing with the SEC, Hohl has control over a total of 51,000 common shares of the company, with 51,000 shares held directly.
SEC Filing: